What is MinervaX?
MinervaX is a clinical-stage biotech firm dedicated to creating novel vaccines, with a primary focus on Group B Streptococcus (GBS). Their lead candidate, AlpN GBS, is being developed for administration to pregnant women and older adults to prevent adverse pregnancy outcomes and severe infections. The company's mission is to tackle significant gaps in current medical treatments, leveraging a team of seasoned scientists and vaccine development experts. MinervaX's efforts are supported by prominent healthcare investment firms, positioning it for significant growth in the vaccine market.
How much funding has MinervaX raised?
MinervaX has raised a total of $199.5M across 4 funding rounds:
Series A
$8.7M
Series B
$57.6M
Private Equity
$76.5M
Other Financing Round
$56.7M
Series A (2014): $8.7M with participation from Lauritzen Fonden and Sunstone
Series B (2020): $57.6M led by Novo Holdings, LF Investment, Wellington Partners, Sunstone Life Science Ventures, Sanofi Ventures, Industrifonden, and Adjuvant Capital
Private Equity (2022): $76.5M supported by REPAIR Impact Fund, Sunstone Life Science Ventures, Trill Impact Ventures, and Pureos Bioventures
Other Financing Round (2023): $56.7M featuring EQT Group, Novo Holdings, Sanofi Ventures, Pureos Bioventures, and OrbiMed
Key Investors in MinervaX
EQT Group
EQT Group is a global investment organization with a thematic approach, targeting high-quality companies in sectors including healthcare. They apply value creation frameworks to enhance revenue, optimize management, and drive strategic growth.
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on life sciences and healthcare investments.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies of strategic interest to Sanofi, particularly in oncology, immunology, and vaccines.
What's next for MinervaX?
With a significant influx of capital, MinervaX is poised to advance its lead vaccine candidate, AlpN GBS, through crucial clinical trial phases. The company's strategic focus on preventing Group B Streptococcus infections in vulnerable populations, such as pregnant women and the elderly, addresses a substantial public health concern. The recent major strategic investment signals strong investor confidence in MinervaX's technology and its potential to achieve regulatory approval and market penetration. Future developments will likely involve expanding clinical studies, potentially exploring additional vaccine targets, and preparing for commercialization, further solidifying its position in the biopharmaceutical landscape.
See full MinervaX company page
